ABBVIE

Roche to present over 40 abstracts on nine blood disorders at the 66th ASH Annual Meeting, highlighting long-term follow-up data for Polivy®, Lunsumio®, and Columvi®, and new combination data, reinforcing commitment to advancing lymphoma patient outcomes.

Doudna and Charpentier's lawyers seek to revoke their European CRISPR–Cas9 patents after an unfavorable EPO opinion, citing procedural strategy rather than conceding patent invalidity, while maintaining broader patent protection in Europe and the US.

DelveInsight's 'Janus Kinase (JAK) Inhibitors Pipeline Insight, 2024' report details the global pipeline, including clinical trials, therapies, MOA, ROA, and key companies like Pfizer, Incyte Corporation, and AbbVie. It highlights emerging therapies like SDC-1801 and Povorcitinib, recent approvals such as upadacitinib for nr-axSpA, and ongoing Phase III trials like Incyte's povorcitinib for hidradenitis suppurativa.

REGENXBIO Inc. announces participation in UBS Global Healthcare Conference (Nov 13, Rancho Palos Verdes), Stifel 2024 Healthcare Conference (Nov 19, New York), and Piper Sandler 36th Annual Healthcare Conference (Dec 5, New York). Webcasts available at www.regenxbio.com.

Eli Lilly missed Q3 estimates, lowered guidance; Merck beat estimates, initiated phase III study; Pfizer beat estimates, raised 2024 guidance; AbbVie beat estimates, acquired Aliada, collaborated with EvolveImmune; Novartis beat estimates, raised 2024 expectations, FDA approved Scemblix expansion.

Regeneron's Eylea sales miss estimates, UCB sees potential in Alzheimer's drug bepranemab, Madrigal's Rezdiffra sales exceed expectations, AbbVie partners with EvolveImmune for cancer drugs, Lundbeck acquires Longboard Pharmaceuticals, and PTC Therapeutics awaits FDA decision on Translarna for Duchenne muscular dystrophy.

HS is a chronic inflammatory disorder affecting hair follicles, characterized by painful, fluid-filled lesions. Humira was the sole FDA-approved therapy until Cosentyx's approval in Oct 2023. Off-label treatments like antibiotics precede biologics. This analysis covers HS treatment trends, Humira's integration, patient progression rates, and therapy combinations, using real-world claims data.

Eli Lilly CEO David Ricks assures investors that knockoff versions of Zepbound aren't affecting sales. Pfizer's Q3 2024 sales surged 31% to $17.7 billion, driven by COVID-19 meds. AbbVie acquires Aliada Therapeutics for $1.4 billion, including Alzheimer's drug candidate ALIA-1758.